Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.98
Humacyte, Inc. incurred term loan of $77,500,000 with Avenue Venture Opportunities Fund II, L.P. at greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu maturing December 1, 2029.
- Instrument
- term loan
- Principal
- $77,500,000
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Rate
- greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu
- Maturity
- December 1, 2029
- Event
- incurrence
Exact text from the filing
On December 15, 2025 (the "Closing Date"), Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global", and together with the Company, the "Borrowers"), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the "Loan Agreement") with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the "Loan Agent") and as lender ("Avenue"), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate that matures on December 1, 2029, consisting of (i) an initial term loan of $40 million (the "First Tranche Term Loan"), which was fully funded on the Closing Date, (ii) a $12.5 million delayed draw term loan (the "Second Tranche Term Loan") which will be made available between October 1, 2026 and March 31, 2027, subject to the satisfaction of certain revenue, regulatory approvals and liquidity conditions, and (iii) a $25 million delayed draw term loan (the "Third Tranche Term Lo
View on SEC.gov